Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
NEW YORK, Dec. 01, 2016 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced two ITI-007 poster presentations at the 55th Annual Meeting of the American College of Neuropsychopharmacology being held in Hollywood, Florida, December 4-8, 2016.
The poster presentation (Abstract M180), titled "Advancing the Clinical Development of Lumateperone (ITI-007) for the Treatment of Schizophrenia – Efficacy Data," will take place on Monday, December 5, 2016, 5:30 pm – 7:30 pm ET during Poster Session I.
The poster presentation (Abstract M173), titled "Advancing the Clinical Development of Lumateperone (ITI-007) for the Treatment of Schizophrenia – Safety and Tolerability Data," will also take place on Monday, December 5, 2016, 5:30 pm – 7:30 pm ET during Poster Session I.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.
Contact: Juan Sanchez, M.D. Vice President Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. Phone: 212-923-3344 Burns McClellan, Inc. Lisa Burns Justin Jackson (Media) Email: [email protected] Phone: 212-213-0006
